On November 30, 2018 SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) ("SELLAS" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapies for a broad range of cancer indications, reported that further correlative data from the Phase 2b trial of nelipepimut-S (NPS, NeuVax) in combination with trastuzumab (Herceptin) for the treatment of women with triple-negative breast cancer (TNBC) will be presented in a poster presentation at the 2018 San Antonio Breast Cancer Symposium (SABCS), taking place December 4-8, 2018 in San Antonio, TX (Press release, Sellas Life Sciences, NOV 30, 2018, View Source;Herceptin-at-the-2018-San-Antonio-Breast-Cancer-Symposium/default.aspx [SID1234531752]). The data will include efficacy results from analysis of key predefined subgroups and the difference in the patterns of disease relapse between the active (NPS plus trastuzumab) versus the control (trastuzumab) arms.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Details for the presentation are as follows:
Title: Subgroups analysis of a multicenter, prospective, randomized, blinded phase 2b trial of trastuzumab + nelipeptimut-S (NeuVax) vs trastuzumab for prevention of recurrence in breast cancer patients
Poster Session 2: Treatment: Immunotherapy (clinical)
Poster Hall Location: Hall 1
Poster Hall Hours: Thursday, December 6, 2018; 8:30 – 10:00 am ET
Abstract ID: P2-09-01
SELLAS previously announced that the full dataset, as well as correlations between clinical response and HLA type, from the Phase 2b trial of nelipepimut-S in combination with trastuzumab were presented in an oral presentation at the 2018 Annual Meeting of the European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) on October 22, 2018 in Munich, Germany, and in a poster presentation at the 2018 Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) Annual Meeting on November 9 and 10, 2018 in Washington, D.C., respectively